Acorda Therapeutics   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Ardsley NY United States (1995)

Organization Overview

First Clinical Trial
2002
NCT01683838
First Marketed Drug
2010
dalfampridine (ampyra)
First NDA Approval
2010
dalfampridine (ampyra)
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ACORDA | Acorda Therapeutics